Lipella Pharmaceuticals Inc.(LIPO)Earnings, Financials & Key Ratios

LIPO•NASDAQ

$0.08

Price updated Jul 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutLipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.Show more

Revenue$536K+19.3%
EBITDA-$5M-7.0%
Net Income-$5M-8.6%
EPS (Diluted)-4.79+22.2%
Gross Margin-573.65%+0.4%
EBITDA Margin-946.69%+10.3%
Operating Margin-947.23%+10.3%
Net Margin-935.25%+9.0%
ROE-198.12%-67.7%

LIPO Price & Volume

Lipella Pharmaceuticals Inc. (LIPO) stock price & volume — 10-year historical chart

Loading chart...

Lipella Pharmaceuticals Faces Severe Capital Depletion Risks

Investment Thesis • Updated 2025Q3

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Capital Access and Dilution

Key Thesis Takeaways

Lipella Pharmaceuticals operates as a pre-commercial biotechnology entity characterized by sporadic revenue generation and persistent operational losses that threaten its long-term viability.
The company's reliance on external financing to fund its clinical pipeline is evidenced by a rapid contraction in total assets from $4.9 million in 2025Q1 to $2.3 million by 2025Q3.
Investors should monitor the firm's ability to secure additional capital, as the current burn rate and negative retained earnings of $19.2 million suggest a high probability of future dilutive equity offerings.

Verdict Logic

the company's rapid depletion of cash reserves to $1.9 million against consistent quarterly operating losses of over $1 million suggests an unsustainable financial trajectory that warrants extreme caution.

LIPO Growth Metrics

Lipella Pharmaceuticals Inc. (LIPO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-5.04%

3 Years27.41%

TTM-61.37%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-25.01%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM41.31%

Return on Capital

10 Years-114.59%

5 Years-114.59%

3 Years-132.79%

Last Year-198.8%

Peers Comparison

Key metrics vs top competitors for Lipella Pharmaceuticals Inc. (LIPO)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
LIPOLipella Pharmaceuticals Inc.Current	$0.08	$363.93K	-0.02	19.29%	-935.25%	-198.12%	—
SIGASIGA Technologies, Inc.	$3.75	$268.97M	11.36	-31.8%	21.61%	10.62%	—
NUVLNuvalent, Inc.	$123.72	$9.1B	-21.15	—	—	-42.78%	—
INVAInnoviva, Inc.	$21.82	$1.61B	6.61	18.52%	118.91%	47.59%	—
PRAXPraxis Precision Medicines, Inc.	$313.50	$9.06B	-23.26	-100%	—	-43.02%	—
ALDXAldeyra Therapeutics, Inc.	$2.28	$137.53M	-4.07	—	—	-0%	—